13 Jan 2017
CEO Dr David Bunton: Finalist - Annual Life Science Award 2017
ReproCELL Europe Ltd's CEO, Dr David Bunton, is one of the finalists nominated for the Life Science Business Leadership Award, part of Scotland's Annual Life Science Awards and Dinner, 2017.
22 Nov 2016
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
ReproCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as the formation of said contract on the same day.
16 Nov 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.